Activating mutations of the KRAS gene are one of the major genomic alterations associated with
tumorigenesis of
non-small cell lung cancer (NSCLC). Thus far, treatment of KRAS-mutant NSCLC remains an unmet medical need. We determined the in vivo treatment responses of 13 KRAS mutant and 14 KRAS wild type NSCLC patient-derived xenografts (PDXs) to agents that target known NSCLC vulnerabilities: the
MEK inhibitor
trametinib, the MDM2 inhibitor KRT-232, and the BCL-XL/BCL-2 inhibitor
navitoclax. The results showed that the
tumor regression rate after single agent
therapy with KRT-232,
trametinib and
navitoclax was 11%, 10% and 0%, respectively. Combination
therapies of
trametinib plus KRT-232 and
trametinib plus
navitoclax led to improved partial response rates over single-agent activity in a subset of PDX models.
Tumor regression was observed in 23% and 50% of PDXs
after treatment with
trametinib plus KRT-232 and
trametinib plus
navitoclax, respectively. The disease control rates in KRAS-mutant PDXs tested were 90%-100%
after treatment with
trametinib plus KRT-232 or plus
navitoclax. A correlation analysis of treatment responses and genomic and proteomic
biomarkers revealed that sensitivity to KRT-232 was significantly associated with TP53 wild-type or STK11 mutant genotypes (P<0.05). The levels of several
proteins, including GSK3b, Nrf2, LKB1/pS334, and SMYD3, were significantly associated with sensitivity to
trametinib plus
navitoclax. Thus, the combination of
trametinib plus KRT-232 or
navitoclax resulted in improved efficacy compared with the agents alone in a subgroup of NSCLC PDX model with KRAS mutations. Expanded clinical trials of these targeted
drug combinations in NSCLC are warranted.